<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149244">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01157429</url>
  </required_header>
  <id_info>
    <org_study_id>Tulane-09-00450</org_study_id>
    <nct_id>NCT01157429</nct_id>
  </id_info>
  <brief_title>D-cycloserine Adjunctive Treatment for Posttraumatic Stress Disorder (PTSD) in Adolescents</brief_title>
  <official_title>D-cycloserine Adjunctive Treatment for PTSD in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show whether D-cycloserine in combination with cognitive
      behavioral therapy (CBT) is more effective than CBT alone to reduce symptoms of
      posttraumatic stress disorder (PTSD) in 13-18 year-old children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While most individuals with PTSD treated with cognitive behavioral therapy (CBT) show
      improvement, they still have some enduring symptoms and functional impairment. Accordingly,
      there is a need for treatment advances. D-cycloserine (DCS), an antibiotic that has been
      used for over 50 years, has also been found to have positive effects on cognition and
      anxiety. DCS was found to enhance learning and memory, and also facilitates extinction of
      fear reactions. However, DCS only produces an extinction effect when paired with behavioral
      training, not when simply given alone. Thus, the medication only needs to be given for seven
      doses in this research and youth do not need to take the medication long term. The research
      also includes a three-month follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2012</completion_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of PTSD symptoms</measure>
    <time_frame>After 12 therapy sessions.</time_frame>
    <description>Symptoms will be determined by a diagnostic interview.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of anxiety symptoms</measure>
    <time_frame>After 12 therapy sessions.</time_frame>
    <description>Symptoms determined by self-report and parent-report checklists.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <condition>PTSD</condition>
  <arm_group>
    <arm_group_label>D-cycloserine plus CBT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Individuals receive 12 sessions of manualized trauma-focused cognitive behavioral therapy plus seven doses of D-cycloserine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals receive 12 sessions of trauma-focused cognitive behavioral therapy plus seven doses of placebo pill.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <description>D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.</description>
    <arm_group_label>D-cycloserine plus CBT</arm_group_label>
    <other_name>Seromycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo pill</intervention_name>
    <description>Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.</description>
    <arm_group_label>Placebo pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Certain number of PTSD symptoms plus functional impairment

          -  Must be able to swallow pills

        Exclusion Criteria:

          -  Serious kidney or liver disease

          -  Epilepsy

          -  Bipolar disorder

          -  Psychosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Scheeringa, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tulane University Health Sciences Center, 1440 Canal St.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 29, 2012</lastchanged_date>
  <firstreceived_date>July 6, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University School of Medicine</investigator_affiliation>
    <investigator_full_name>Michael S. Scheeringa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Cognitive Behavior Therapy</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Pharmacotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cycloserine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
